Efficacy and safety of <scp>CT‐P13</scp>, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study

Abstract

CT-P13 appears to have comparable efficacy, safety, and interchangeability with its originator in the treatment of IBD. Further prospective studies with long-term follow-up periods will be needed to confirm the biosimilarity of CT-P13.